Table 1. Adverse Events Occurring in > 10% of Patients With Relapsed or Refractory DLBCL and ≥ 5% in the Polatuzumab Vedotin Plus Bendamustine and Rituximab Group.

	Polatuzumab vedotin + BR (n = 45)		BR (n = 39)
Adverse events by body system	All grades, %	Grade 3 or higher, %	All grades, %	Grade 3 or higher, %
Blood and lymphatic system disorders
Neutropenia	49	42	44	36
Thrombocytopenia	49	40	33	26
Anemia	47	24	28	18
Lymphopenia	13	13	8	8
Nervous system disorders
Peripheral neuropathy	40	0	8	0
Dizziness	13	0	8	0
Gastrointestinal disorders
Diarrhea	38	4.4	28	5
Vomiting	18	2.2	13	0
General disorders
Infusion-related reaction	18	2.2	8	0
Pyrexia	33	2.2	23	0
Decreased appetite	27	2.2	21	0
Infections
Pneumonia	22	16a	15	2.6b
Upper respiratory tract infection	13	0	8	0
Investigations
Weight decreased	16	2.2	8	2.6
Metabolism and nutrition disorders
Hypokalemia	16	9	10	2.6
Hypoalbuminemia	13	2.2	8	0
Hypocalcemia	11	2.2	5	0

Note. The table includes a combination of grouped and ungrouped terms. Events were graded using NCI CTCAE version 4. Reprinted with permission from Genentech, Inc. (2019).

^aIncludes 2 events with fatal outcome.

^bIncludes 1 event with fatal outcome.